MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Total Liabilities 2011-2026 | PCRX
Annual Total Liabilities Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 775 M | 704 M | 906 M | 1.34 B | 655 M | 476 M | 368 M | 349 M | 172 M | 171 M | 155 M | 129 M | 46.2 M | 65.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.34 B | 46.2 M | 451 M |
Quarterly Total Liabilities Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 570 M | 779 M | 788 M | 775 M | 772 M | 768 M | 691 M | 704 M | 703 M | 734 M | 755 M | 906 M | 964 M | - | 1.18 B | 1.34 B | 637 M | 639 M | 637 M | 655 M | 655 M | 655 M | 655 M | 476 M | 476 M | 476 M | 476 M | 368 M | 368 M | 368 M | 368 M | 349 M | 349 M | 349 M | 349 M | 172 M | 172 M | 172 M | 172 M | 169 M | 169 M | 169 M | 169 M | 155 M | 155 M | 155 M | 155 M | 129 M | 129 M | 129 M | 129 M | 46.2 M | 46.2 M | 46.2 M | 46.2 M | 65.2 M | 65.2 M | 65.2 M | 65.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.34 B | 46.2 M | 426 M |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
12.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
430 M | $ 0.97 | 2.36 % | $ 104 M |  Canada |
 |
Aurora Cannabis
ACB
|
244 M | $ 3.31 | 1.53 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
7.14 M | $ 0.63 | 16.11 % | $ 11 M |  China |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
218 M | $ 2.52 | 5.44 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 8.05 | -1.71 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
53 M | $ 3.05 | 7.77 % | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.1 | 1.8 % | $ 1.86 B | Canada |
 |
Harrow Health
HROW
|
347 M | $ 34.0 | 2.16 % | $ 1.25 B | USA |
 |
Assertio Holdings
ASRT
|
173 M | $ 14.0 | 4.71 % | $ 89.6 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
249 M | $ 4.68 | 0.86 % | $ 302 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
24 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
9.51 M | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
7.49 M | $ 5.86 | -3.46 % | $ 231 M | USA |
 |
Rockwell Medical
RMTI
|
30.9 M | $ 1.02 | -2.86 % | $ 23.8 M | USA |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
235 M | $ 1.36 | 0.74 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
9.65 M | $ 0.88 | -6.09 % | $ 43.9 M | USA |
 |
Solid Biosciences
SLDB
|
52.5 M | $ 7.14 | 1.56 % | $ 625 M | USA |
 |
Organogenesis Holdings
ORGO
|
113 M | $ 2.47 | 3.65 % | $ 325 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
36.5 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
5.6 B | $ 9.57 | 3.46 % | $ 1.33 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 2.55 | 4.94 % | $ 3.16 M | USA |
 |
Tilray
TLRY
|
977 M | $ 6.45 | 3.86 % | $ 3.99 B | Canada |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
14 M | $ 2.31 | 3.12 % | $ 24.1 M | USA |
 |
Veru
VERU
|
28.1 M | $ 2.3 | 1.32 % | $ 310 M | USA |
 |
Viatris
VTRS
|
28.9 B | $ 13.29 | 0.68 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.76 | 11.88 % | $ 3.28 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |